MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Net Income towards Common Stockholders of $15.1 million for Q4 2025, up 138.3% on a YoY basis from $6.3 million in Q4 2024, and up 129.87% quarter-over-quarter from -$50.5 million in Q3 2025.
MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Net Income towards Common Stockholders for 9 years, with the latest figure at $15.1 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 138.3% year-over-year to $15.1 million; the trailing twelve-month figure through Dec 2025 stood at -$114.2 million (up 22.73% YoY), and the FY2025 full-year result was -$114.2 million, up 22.73% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at $15.1 million, up from -$50.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $20.2 million in Q4 2023, with the low at -$50.5 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$27.8 million across 5 years, with a median of -$30.7 million in 2022.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders tumbled 303.37% — and 2023, when it jumped 174.01%.
- MeiraGTx Holdings' Net Income towards Common Stockholders stood at -$9.9 million in 2021, then plunged by 175.55% to -$27.3 million in 2022, then jumped by 174.01% to $20.2 million in 2023, then slumped by 294.9% to -$39.4 million in 2024, then surged by 138.3% to $15.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at $15.1 million (Q4 2025), -$50.5 million (Q3 2025), and -$38.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 15.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.09 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Jun 30, 2025 | -38.80 Mn |
| Mar 31, 2025 | -39.98 Mn |
| Dec 31, 2024 | -39.40 Mn |
| Sep 30, 2024 | -39.33 Mn |
| Jun 30, 2024 | -48.62 Mn |
| Mar 31, 2024 | -20.44 Mn |
| Dec 31, 2023 | 20.22 Mn |
| Sep 30, 2023 | -44.30 Mn |
| Jun 30, 2023 | -29.58 Mn |
| Mar 31, 2023 | -30.36 Mn |
| Dec 31, 2022 | -27.31 Mn |
| Sep 30, 2022 | -37.28 Mn |
| Jun 30, 2022 | -33.97 Mn |
| Mar 31, 2022 | -31.05 Mn |
| Dec 31, 2021 | -9.91 Mn |
| Sep 30, 2021 | -25.95 Mn |
| Jun 30, 2021 | -20.09 Mn |
| Mar 31, 2021 | -23.62 Mn |